Table 3.
Adverse events and toxicities.
| Variables | n = 34 (%) |
|---|---|
| Major adverse events | 18 (53%) |
| I–II degree | 11 (32%) |
| III degree | 6 (18%) |
| IV degree | 1 (3%) |
| Hematologic toxicities | 13 (38%) |
| I–II degree | 10 (29%) |
| III degree | 2 (6%) |
| IV degree | 1 (3%) |
| Leukopenia | 8 (24%) |
| I–II degree | 6 (18%) |
| III degree | 1 (3%) |
| IV degree | 1 (3%) |
| Thrombocytopenia | 11 (32%) |
| I–II degree | 8 (24%) |
| III degree | 2 (6%) |
| IV degree | 1 (3%) |
| Elevation of hepatic aminotransferases | 10 (29%) |
| I degree | 4 (12%) |
| II degree | 3 (9%) |
| III degree | 3 (9%) |
| Radiculitis | 4 (12%) |
| I degree | 2 (6%) |
| II degree | 1 (3%) |
| III degree | 1 (3%) |
| Leukoencephalopathy (n = 17) | 8 (47%) |
| I–II degree | 7 (41%) |
| III degree | 1 (6%) |